Cargando…
Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955592/ https://www.ncbi.nlm.nih.gov/pubmed/20849623 http://dx.doi.org/10.1186/1748-717X-5-81 |
_version_ | 1782188046580449280 |
---|---|
author | Baba, Fumiya Shibamoto, Yuta Ogino, Hiroyuki Murata, Rumi Sugie, Chikao Iwata, Hiromitsu Otsuka, Shinya Kosaki, Katsura Nagai, Aiko Murai, Taro Miyakawa, Akifumi |
author_facet | Baba, Fumiya Shibamoto, Yuta Ogino, Hiroyuki Murata, Rumi Sugie, Chikao Iwata, Hiromitsu Otsuka, Shinya Kosaki, Katsura Nagai, Aiko Murai, Taro Miyakawa, Akifumi |
author_sort | Baba, Fumiya |
collection | PubMed |
description | BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung cancer (NSCLC) treated with different doses depending on tumor diameter. METHODS: Between February 2004 and November 2008, 124 patients with stage I NSCLC underwent SBRT. Total doses of 44, 48, and 52 Gy were administered for tumors with a longest diameter of less than 1.5 cm, 1.5-3 cm, and larger than 3 cm, respectively. All doses were given in 4 fractions. RESULTS: For all 124 patients, overall survival was 71%, cause-specific survival was 87%, progression-free survival was 60%, and local control was 80%, at 3 years. The 3-year overall survival was 79% for 85 stage IA patients treated with 48 Gy and 56% for 37 stage IB patients treated with 52 Gy (p = 0.05). At 3 years, cause-specific survival was 91% for the former group and 79% for the latter (p = 0.18), and progression-free survival was 62% versus 54% (p = 0.30). The 3-year local control rate was 81% versus 74% (p = 0.35). The cumulative incidence of grade 2 or 3 radiation pneumonitis was 11% in stage IA patients and 30% in stage IB patients (p = 0.02). CONCLUSIONS: There was no difference in local control between stage IA and IB tumors despite the difference in tumor size. The benefit of increasing the SBRT dose for larger tumors should be investigated further. |
format | Text |
id | pubmed-2955592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29555922010-10-16 Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size Baba, Fumiya Shibamoto, Yuta Ogino, Hiroyuki Murata, Rumi Sugie, Chikao Iwata, Hiromitsu Otsuka, Shinya Kosaki, Katsura Nagai, Aiko Murai, Taro Miyakawa, Akifumi Radiat Oncol Research BACKGROUND: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung cancer (NSCLC) treated with different doses depending on tumor diameter. METHODS: Between February 2004 and November 2008, 124 patients with stage I NSCLC underwent SBRT. Total doses of 44, 48, and 52 Gy were administered for tumors with a longest diameter of less than 1.5 cm, 1.5-3 cm, and larger than 3 cm, respectively. All doses were given in 4 fractions. RESULTS: For all 124 patients, overall survival was 71%, cause-specific survival was 87%, progression-free survival was 60%, and local control was 80%, at 3 years. The 3-year overall survival was 79% for 85 stage IA patients treated with 48 Gy and 56% for 37 stage IB patients treated with 52 Gy (p = 0.05). At 3 years, cause-specific survival was 91% for the former group and 79% for the latter (p = 0.18), and progression-free survival was 62% versus 54% (p = 0.30). The 3-year local control rate was 81% versus 74% (p = 0.35). The cumulative incidence of grade 2 or 3 radiation pneumonitis was 11% in stage IA patients and 30% in stage IB patients (p = 0.02). CONCLUSIONS: There was no difference in local control between stage IA and IB tumors despite the difference in tumor size. The benefit of increasing the SBRT dose for larger tumors should be investigated further. BioMed Central 2010-09-17 /pmc/articles/PMC2955592/ /pubmed/20849623 http://dx.doi.org/10.1186/1748-717X-5-81 Text en Copyright ©2010 Baba et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Baba, Fumiya Shibamoto, Yuta Ogino, Hiroyuki Murata, Rumi Sugie, Chikao Iwata, Hiromitsu Otsuka, Shinya Kosaki, Katsura Nagai, Aiko Murai, Taro Miyakawa, Akifumi Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title_full | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title_fullStr | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title_full_unstemmed | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title_short | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
title_sort | clinical outcomes of stereotactic body radiotherapy for stage i non-small cell lung cancer using different doses depending on tumor size |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955592/ https://www.ncbi.nlm.nih.gov/pubmed/20849623 http://dx.doi.org/10.1186/1748-717X-5-81 |
work_keys_str_mv | AT babafumiya clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT shibamotoyuta clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT oginohiroyuki clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT muratarumi clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT sugiechikao clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT iwatahiromitsu clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT otsukashinya clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT kosakikatsura clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT nagaiaiko clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT muraitaro clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize AT miyakawaakifumi clinicaloutcomesofstereotacticbodyradiotherapyforstageinonsmallcelllungcancerusingdifferentdosesdependingontumorsize |